Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Faces Price Pressures In US On Generic Gleevec

Executive Summary

India’s biggest drug-maker, Sun Pharmaceutical Industries Ltd., has reported a more than tripling of its quarterly profit thanks to US sales of a generic version of Novartis AG’s leukemia blockbuster Gleevec. But now its 180-day sales exclusivity window has closed and generic rivals are launching in the US market, pushing prices down.

Advertisement

Related Content

Sun Chief Sees ‘New Normal’ For First-To-File ANDAs Amid US Price Pressure
Manufacturing Woes Continue To Plague Dr Reddy’s; Are Generic Gleevec Launch Plans Under Threat?
Daiichi Arbitration Case Bares Trail Of Deception At Ranbaxy
Sun Builds On Tildrakizumab Hopes With Almirall Pact

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097139

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel